IBA’s Proteus TK2, a Two-Room Turnkey Proton Therapy Center, to Include Patient Management Solutions from Elekta

Details highlighted at the 50th meeting of PTCOG, Philadelphia, Penn., USA and the 11th Biennial ESTRO Conference, London, UK

Philadelphia and London United Kingdom — Tuesday, May 10, 2011

Elekta, a human care company pioneering significant innovations and clinical solutions for treating cancer and brain disorders, will integrate cancer workflow and patient management tools into the Proteus TK2™, a turnkey proton therapy center from Belgium-based Ion Beam Applications (IBA). The IBA proton therapy system includes a cyclotron, beam line, gantry treatment room and a fixed-beam treatment room.

IBA and Elekta announced their collaboration at the European Society of Therapeutic Radiology and Oncology (ESTRO) Anniversary Congress in London, UK, 8-12 May 2011, and the Particle Therapy Co-Operative Group (PTCOG) conference in Philadelphia, Penn., USA, 8-14 May 2011.

“IBA’s Proteus TK2 is a ‘no worries’ approach for a cancer center’s executive to successfully build a proton therapy department for their patients,” says Pierre Mottet, Chief Executive Officer of IBA. “It covers everything from project planning to financing, construction, proton system installation and day-to-day operations and service. Incorporating Elekta’s integrated patient management tools provides a consistently reliable diagnostic and treatment system in which clinicians and patients can completely trust.”

Elekta software and devices included in the Proteus TK2 center are the MOSAIQ® oncology information system designed specifically for oncology settings, including proton therapy clinics; auto-segmentation solutions, comprehensive treatment planning functionality that supports conventional radiation and proton-beam therapies – including uniform scanning, scattering and spot scanning with Intensity Modulated Proton Therapy; non-invasive patient immobilization and positioning systems that provide accurate and reproducible positioning for proton therapy; and respiratory motion management to help reduce treatment margins.

“Elekta’s world leading patient management solutions, which deliver oncology optimized workflow solutions will enhance the patient experience, reduce clinical risk and maximize return on investment,” says Stewart Pegrum, Director Particle Therapy, Elekta. “And, clinicians know Elekta will refine its software and hardware with every advance in proton therapy technology and treatment.”

 

###

About Elekta

Elekta is a human care company pioneering significant innovations and clinical solutions for treating cancer and brain disorders. The company develops sophisticated, state-of-the-art tools and treatment planning systems for radiation therapy, radiosurgery and brachytherapy, as well as workflow enhancing software systems across the spectrum of cancer care. Stretching the boundaries of science and technology, providing intelligent and resource-efficient solutions that offer confidence to both healthcare providers and patients, Elekta aims to improve, prolong and even save patient lives.

Elekta is a human care company pioneering significant innovations and clinical solutions for treating cancer and brain disorders. The company develops sophisticated, state-of-the-art tools and treatment planning systems for radiation therapy, radiosurgery and brachytherapy, as well as workflow enhancing software systems across the spectrum of cancer care. Stretching the boundaries of science and technology, providing intelligent and resource-efficient solutions that offer confidence to both healthcare providers and patients, Elekta aims to improve, prolong and even save patient lives.

Today, Elekta solutions in oncology and neurosurgery are used in over 6,000 hospitals worldwide. Elekta employs around 3,300 employees globally. The corporate headquarters is located in Stockholm, Sweden, and the company is listed on the Nordic Exchange under the ticker EKTAb. Website: www.elekta.com.

About IBA

IBA develops and markets leading-edge technologies, pharmaceuticals and tailor-made solutions for healthcare with a focus on cancer diagnosis and therapy. Leveraging on its scientific expertise, IBA is also active in the field of industrial sterilization and ionization. Listed on the pan-European stock exchange EURONEXT, IBA is included in the BelMid Index. (IBA: Reuters IBAB.BR and Bloomberg IBAB.BB).

Website: www.iba-worldwide.com

Press Releases

For further information, please contact

Stina Thorman, Vice President Corporate Communications, Elekta AB
Tel: +46 8 587 254 37
Email: stina.thorman@elekta.com
Time zone: CET: Central European Time

Michelle Lee Joiner, Director, Global Public Relations and Brand Management, Elekta
Tel: +1 770-670-2447
Email: michelle.joiner@elekta.com
Time zone: ET: Eastern Time